The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Antibody–drug conjugates: targeted drug delivery for cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,676
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1480 · Cited by 1,382
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M. C., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0789 · Cited by 1,247
Self-citationDevelopment of potent monoclonal antibody auristatin conjugates for cancer therapy
Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt832 · Cited by 1,206
Self-citationTargeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs
Chari, R. V. J. (2008) · Accounts of Chemical Research · doi:10.1021/ar700108g · Cited by 815
Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies
Ducry, L., & Stump, B. (2010) · Bioconjugate Chemistry · doi:10.1021/bc9002019 · Cited by 625
Hamann, P. R., Hinman, L. M., Hollander, I., Beyer, C. F., Lindh, D., Holcomb, R., Hallett, W., Tsou, H.-R., Upeslacis, J., Shochat, D., et al. (2002) · Bioconjugate Chemistry · doi:10.1021/bc010021y · Cited by 594
Erickson, H. K., Park, P. U., Widdison, W. C., Kovtun, Y. V., Garrett, L. M., Hoffman, K., Lutz, R. J., Goldmacher, V. S., & Blättler, W. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4489 · Cited by 584
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
Schmidt, M. M., & Wittrup, K. D. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0195 · Cited by 576
Doronina, S. O., Mendelsohn, B. A., Bovee, T. D., Cerveny, C. G., Alley, S. C., Meyer, D. L., Oflazoglu, E., Toki, B. E., Sanderson, R. J., Zabinski, R. F., et al. (2006) · Bioconjugate Chemistry · doi:10.1021/bc0502917 · Cited by 515
Self-citationContribution of Linker Stability to the Activities of Anticancer Immunoconjugates
Alley, S. C., Benjamin, D. R., Jeffrey, S. C., Okeley, N. M., Meyer, D. L., Sanderson, R. J., & Senter, P. D. (2008) · Bioconjugate Chemistry · doi:10.1021/bc7004329 · Cited by 479
Self-citationAntibody-Drug Conjugates for Cancer Therapy
Carter, P. J., & Senter, P. D. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e318172d704 · Cited by 429
Self-citationPotent antibody drug conjugates for cancer therapy
Senter, P. D. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.03.023 · Cited by 401
Self-citationIntracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
Okeley, N. M., Miyamoto, J. B., Zhang, X., Sanderson, R. J., Benjamin, D. R., Sievers, E. L., Senter, P. D., & Alley, S. C. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2069 · Cited by 393
Self-citationReduction−Alkylation Strategies for the Modification of Specific Monoclonal Antibody Disulfides
Sun, M. M. C., Beam, K. S., Cerveny, C. G., Hamblett, K. J., Blackmore, R. S., Torgov, M. Y., Handley, F. G. M., Ihle, N. C., Senter, P. D., & Alley, S. C. (2005) · Bioconjugate Chemistry · doi:10.1021/bc050201y · Cited by 370
Self-citationSemisynthetic Maytansine Analogues for the Targeted Treatment of Cancer
Widdison, W. C., Wilhelm, S. D., Cavanagh, E. E., Whiteman, K. R., Leece, B. A., Kovtun, Y., Goldmacher, V. S., Xie, H., Steeves, R. M., Lutz, R. J., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060319f · Cited by 309
Sutherland, M. S. K., Sanderson, R. J., Gordon, K. A., Andreyka, J., Cerveny, C. G., Yu, C., Lewis, T. S., Meyer, D. L., Zabinski, R. F., Doronina, S. O., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510026200 · Cited by 296
Self-citationSmith, L. M., Nesterova, A., Ryan, M. C., Duniho, S., Jonas, M., Anderson, M., Zabinski, R. F., Sutherland, M. K., Gerber, H.-P., Van Orden, K. L., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604437 · Cited by 286
In vivo Drug-Linker Stability of an Anti-CD30 Dipeptide-Linked Auristatin Immunoconjugate
Sanderson, R. J., Hering, M. A., James, S. F., Sun, M. M. C., Doronina, S. O., Siadak, A. W., Senter, P. D., & Wahl, A. F. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.843.11.2 · Cited by 285
Self-citationMonoclonal Antibodies as Innovative Therapeutics
Reichert, J. (2008) · Current Pharmaceutical Biotechnology · doi:10.2174/138920108786786358 · Cited by 265
Polson, A. G., Calemine-Fenaux, J., Chan, P., Chang, W., Christensen, E., Clark, S., de Sauvage, F. J., Eaton, D., Elkins, K., Elliott, J. M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2250 · Cited by 252
Erickson, H. K., Widdison, W. C., Mayo, M. F., Whiteman, K., Audette, C., Wilhelm, S. D., & Singh, R. (2010) · Bioconjugate Chemistry · doi:10.1021/bc900315y · Cited by 246
Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment
McDonagh, C. F., Turcott, E., Westendorf, L., Webster, J. B., Alley, S. C., Kim, K., Andreyka, J., Stone, I., Hamblett, K. J., Francisco, J. A., et al. (2006) · Protein Engineering Design and Selection · doi:10.1093/protein/gzl013 · Cited by 243
Self-citationLarson, R., Boogaerts, M., Estey, E., Karanes, C., Stadtmauer, E., Sievers, E., Mineur, P., Bennett, J., Berger, M., Eten, C., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402677 · Cited by 221
Ikeda, H., Hideshima, T., Fulciniti, M., Lutz, R. J., Yasui, H., Okawa, Y., Kiziltepe, T., Vallet, S., Pozzi, S., Santo, L., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2867 · Cited by 203
Ross, S., Spencer, S. D., Holcomb, I. N., Tan, C., Hongo, J.-A., Devaux, B., Rangell, L. K., Keller, G. A., Schow, P. W., Steeves, R. M., et al. (2002) · PubMed · Cited by 144
Antibody-Drug Conjugate Targets
Teicher, B. A. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909790192365 · Cited by 142
Ma, D., Hopf, C. E., Malewicz, A. D., Donovan, G. P., Senter, P. D., Goeckeler, W. F., Maddon, P. J., & Olson, W. C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2107 · Cited by 139
Self-citationThe Pharmacologic Basis for Antibody-Auristatin Conjugate Activity
Alley, S. C., Zhang, X., Okeley, N. M., Anderson, M. E., Law, C., Senter, P. D., & Benjamin, D. R. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.155549 · Cited by 136
Self-citationEphB2 as a Therapeutic Antibody Drug Target for the Treatment of Colorectal Cancer
Mao, W., Luis, E., Ross, S., Silva, J., Tan, C., Crowley, C. W., Chui, C. H., Franz, G., Senter, P. D., Koeppen, H., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1047 · Cited by 127
Self-citationEfficient Elimination of B-Lineage Lymphomas by Anti-CD20–Auristatin Conjugates
Law, C., Cerveny, C. G., Gordon, K. A., Klussman, K., Mixan, B. J., Chace, D. F., Meyer, D. L., Doronina, S. O., Siegall, C. B., Francisco, J. A., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1028 · Cited by 116
Self-citationOflazoglu, E., Stone, I. J., Gordon, K. A., Wood, C. G., Repasky, E. A., Grewal, I. S., Law, C., & Gerber, H. P. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0916 · Cited by 114
Smith, L. M., Nesterova, A., Alley, S. C., Torgov, M. Y., & Carter, P. J. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0026 · Cited by 108
Self-citationCarbonic Anhydrase IX Expression in Clear Cell Renal Cell Carcinoma
Al‐Ahmadie, H. A., Alden, D., Qin, L., et al. (2008) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181570343 · Cited by 103
Anti-CD30 diabody-drug conjugates with potent antitumor activity
Kim, K. M., McDonagh, C. F., Westendorf, L., Brown, L. L., Sussman, D. R., Feist, T., Lyon, R. P., Alley, S. C., Okeley, N. M., Zhang, X., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0388 · Cited by 99
Self-citationChen, Y., Clark, S., Wong, T., Chen, Y., Chen, Y., Dennis, M. S., Luis, E., Zhong, F., Bheddah, S., Koeppen, H., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4512 · Cited by 94
EphA2 Immunoconjugate as Molecularly Targeted Chemotherapy for Ovarian Carcinoma
Lee, J., Han, H. D., Shahzad, M. M. K., Kim, S. W., Mangala, L. S., Nick, A. M., Lü, C., Langley, R. R., Schmandt, R. E., Kim, H., et al. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp231 · Cited by 90
Antibody targeting of B-cell maturation antigen on malignant plasma cells
Ryan, M. C., Hering, M. A., Peckham, D., McDonagh, C. F., Brown, L. L., Kim, K. M., Meyer, D. L., Zabinski, R. F., Grewal, I. S., & Carter, P. J. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0464 · Cited by 89
Afar, D., Bhaskar, V., Ibsen, E. M., Breinberg, D., Henshall, S. M., Kench, J. G., Drobnjak, M., Powers, R., Wong, M. H. L., Evangelista, F., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.921.3.8 · Cited by 81
Strickland, L. A., Ross, J., Williams, S. A., Ross, S., Romero, M., Spencer, S. D., Erickson, R., Sutcliffe-Goulden, J., Verbeke, C. S., Polakis, P. G., et al. (2009) · The Journal of Pathology · doi:10.1002/path.2545 · Cited by 71
DiJoseph, J. F., Dougher, M. M., Armellino, D. C., Kalyandrug, L. B., Kunz, A., Boghaert, E. R., Hamann, P. R., & Damle, N. K. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0260-5 · Cited by 64
Boghaert, E. R., Sridharan, L., Khandke, K. M., Armellino, D. C., Ryan, M., Myers, K. A., Harrop, R., Kunz, A., Hamann, P., Marquette, K., et al. (2008) · International Journal of Oncology · doi:10.3892/ijo.32.1.221 · Cited by 41
αv Integrin-Targeted Immunoconjugates Regress Established Human Tumors in Xenograft Models
Chen, Q., Millar, H. J., McCabe, F. L., Manning, C. D., Steeves, R. M., Lai, K., Kellogg, B. A., Lutz, R. J., Trikha, M., Nakada, M. T., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0026 · Cited by 35
Antibody‐Drug Conjugate Therapy
Alley, S. C., Benjamin, D. R., & Law, C. (2009) · Wiley eBooks · doi:10.1002/9780470485408.ch35 · Cited by 3
Self-citation
Cited by
Natural products: A continuing source of novel drug leads
Cragg, G. M., & Newman, D. J. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.02.008 · Cited by 2,906
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.02.007 · Cited by 1,834
The evolution of commercial drug delivery technologies
Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361
Metadata
- Authors
- Alley, S. C., Okeley, N. M., & Senter, P. D.
- Venue
- Current Opinion in Chemical Biology
- Publisher
- Elsevier BV
- Published
- 2010-08
- Volume
- 14
- Issue
- 4
- Pages
- 529-537
- ISSN
- 1367-5931 (ISSN-L)
- OpenAlex
- W2034609970
- Cited by
- 656
- References
- 44
- FWCI
- 5.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.